GlassScriptPhysician profile
Pooja Srikanth
NPI 1023442126
$4,935.81
in general payments reported to CMS, 2019-2025
41 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $372 · 2021: $1,619 · 2022: $1,447 · 2023: $842 · 2024: $204 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.02 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $503.20 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $394.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $389.72 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.87 | 2020-2024 | Xifaxan |
| Pfizer INC. | $290.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.32 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $202.65 | 2021-2024 | |
| Esperion Therapeutics, INC. | $157.25 | 2020-2021 | |
| Glaxosmithkline, LLC. | $144.91 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $142.32 | 2022-2025 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $129.94 | 2020-2022 | |
| Coloplast Corp | $126.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.69 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Srikanth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.